Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaFrancesco Lo‐Coco, Uwe Platzbecker, Giorgina Specchia et al.|New England Journal of Medicine|2013Cited by 1.6k
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Corrado Tarella, Federica De Marco et al.|Blood|2008Cited by 253
Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological MalignanciesGiuseppe Messina, Benedetto Bruno, Luisa Giaccone et al.|Biology of Blood and Marrow Transplantation|2012Cited by 30
A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.Corrado Tarella, Paolo Corradini, Marco Ladetto et al.|Blood|2009Cited by 4
Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment.Marco Ladetto, Corrado Tarella, Federica De Marco et al.|Blood|2007Cited by 2